Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPL | P05186 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | ALPI | P09923 | 2/20 | 0.43 |
| ▸ | ALPG | P10696 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5635281 | 0.76 | EZH2 (0.44) | HPGDMAPTALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL12479526 | 0.74 | GLA (0.43) | GAAALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL10903296 | 0.73 | KMT2A (0.67) | ALPLKMT2AALPIALPGMEN1 | |
| SCHEMBL5634616 | 0.72 | HDAC3 (0.46) | ALPLKMT2AMEN1GAAKDM4E | |
| SCHEMBL6597169 | 0.72 | ALDH1A1 (0.41) | KMT2AGAAMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL13604501 | 0.72 | DPP4 (0.49) | KMT2AMEN1HPGDGAAMAPT | |
| SCHEMBL11860116 | 0.72 | DPP4 (0.49) | KMT2AMEN1HPGDGAAMAPT | |
| SCHEMBL27928186 | 0.72 | DPP4 (0.49) | KMT2AMEN1HPGDGAAMAPT | |
| SCHEMBL17144545 | 0.71 | MC4R (0.63) | HPGDALDH1A1 | |
| SCHEMBL11350842 | 0.71 | POLB (0.58) | ALPLKMT2AALPIALPGMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8404690-B2 | Piperazine-2-carboxamide derivatives | MERCK SERONO SA (CH) | 2013-03-26 | — | — | US | disclosed |
| US-20070142391-A1 | Piperazine-2-carboxamide derivatives | MERCK SERONO SA (CH) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142391-A1 | Piperazine-2-carboxamide derivatives | P2RX5, P2RX2, NPY5R | ALPL 4789/4885KMT2A 396/4885ALPI 4313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.